Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs.

This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...

If you purchased or acquired securities in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 ...

WeightWatchers is now only offering Wegovy while other telehealth providers defiantly hang on to compounded alternatives.

STORY: Novo Nordisk is ramping up lawsuits against U.S. companies selling cheaper versions of its weight-loss drug Wegovy. But one firm remains conspicuously absent: Hims & Hers.This telehealth ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...

Novo Nordisk remains the GLP-1 leader with over 65% market share. Read an in-depth BVO stock analysis and why we rate it as a ...